

Maximilian Diehn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8153962/publications.pdf>

Version: 2024-02-01

224
papers

36,737
citations

12330

69
h-index

3732

179
g-index

230
all docs

230
docs citations

230
times ranked

47518
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust enumeration of cell subsets from tissue expression profiles. <i>Nature Methods</i> , 2015, 12, 453-457.	19.0	8,460
2	The prognostic landscape of genes and infiltrating immune cells across human cancers. <i>Nature Medicine</i> , 2015, 21, 938-945.	30.7	2,505
3	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , 2019, 37, 773-782.	17.5	2,396
4	Association of reactive oxygen species levels and radioresistance in cancer stem cells. <i>Nature</i> , 2009, 458, 780-783.	27.8	2,232
5	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. <i>Nature Medicine</i> , 2014, 20, 548-554.	30.7	1,771
6	Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells. <i>Cell</i> , 2009, 138, 592-603.	28.9	1,130
7	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016, 34, 547-555.	17.5	837
8	Individuality and variation in gene expression patterns in human blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1896-1901.	7.1	723
9	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	9.4	701
10	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 650.	7.1	696
11	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.	1.6	668
12	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	12.8	520
13	Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 5814-5819.	7.1	445
14	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704.	21.4	423
15	Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1529.	7.1	412
16	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5213-5218.	7.1	408
17	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	27.8	379
18	SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. <i>Nucleic Acids Research</i> , 2003, 31, 219-223.	14.5	376

#	ARTICLE	IF	CITATIONS
19	Stereotyped and specific gene expression programs in human innate immune responses to bacteria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 972-977.	7.1	371
20	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016, 8, 364ra155.	12.4	348
21	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	1.6	313
22	Gene Expression Patterns in Ovarian Carcinomas. <i>Molecular Biology of the Cell</i> , 2003, 14, 4376-4386.	2.1	302
23	Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11796-11801.	7.1	300
24	Cell-type specific gene expression profiles of leukocytes in human peripheral blood. <i>BMC Genomics</i> , 2006, 7, 115.	2.8	275
25	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
26	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , 2015, 125, 3679-3687.	1.4	270
27	Isolation and Molecular Characterization of Cancer Stem Cells in MMTV- <i>Wnt-1</i> Murine Breast Tumors. <i>Stem Cells</i> , 2008, 26, 364-371.	3.2	262
28	Biochemical Interactions Integrating Itk with the T Cell Receptor-initiated Signaling Cascade. <i>Journal of Biological Chemistry</i> , 2000, 275, 2219-2230.	3.4	244
29	Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. <i>Nature Genetics</i> , 2000, 25, 58-62.	21.4	241
30	Role of <i>KEAP1</i> and <i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. <i>Cancer Discovery</i> , 2017, 7, 86-101.	9.4	239
31	Predicting HLA class II antigen presentation through integrated deep learning. <i>Nature Biotechnology</i> , 2019, 37, 1332-1343.	17.5	218
32	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
33	FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. <i>Bioinformatics</i> , 2014, 30, 3390-3393.	4.1	212
34	Cancer Stem Cells and Radiotherapy: New Insights Into Tumor Radioresistance. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1755-1757.	6.3	207
35	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	28.9	206
36	Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of <i>c-myc</i> and its regulated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8886-8891.	7.1	204

#	ARTICLE	IF	CITATIONS
37	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	13.2	201
38	Degradation of Proteins from the ER of <i>S. cerevisiae</i> Requires an Intact Unfolded Protein Response Pathway. <i>Molecular Cell</i> , 2000, 5, 729-735.	9.7	171
39	Transcriptional programs activated by exposure of human prostate cancer cells to androgen. <i>Genome Biology</i> , 2002, 3, RESEARCH0032.	9.6	158
40	Early-Stage Non- ¹⁸ F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. <i>Radiology</i> , 2016, 281, 270-278.	7.3	152
41	Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. <i>Lung Cancer</i> , 2015, 89, 50-56.	2.0	151
42	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	17.5	151
43	Reprogramming the immunological microenvironment through radiation and targeting Axl. <i>Nature Communications</i> , 2016, 7, 13898.	12.8	150
44	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. <i>Gastroenterology</i> , 2020, 158, 494-505.e6.	1.3	147
45	In Vivo Regulation of Human Skeletal Muscle Gene Expression by Thyroid Hormone. <i>Genome Research</i> , 2002, 12, 281-291.	5.5	143
46	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. <i>Cancer Discovery</i> , 2019, 9, 500-509.	9.4	143
47	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	28.9	138
48	Stereotactic Ablative Radiotherapy Should Be Combined With a Hypoxic Cell Radiosensitizer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 323-327.	0.8	131
49	Therapeutic Implications of the Cancer Stem Cell Hypothesis. <i>Seminars in Radiation Oncology</i> , 2009, 19, 78-86.	2.2	130
50	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.	2.5	120
51	Atlas of clinically distinct cell states and ecosystems across human solid tumors. <i>Cell</i> , 2021, 184, 5482-5496.e28.	28.9	116
52	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. <i>Cancer Discovery</i> , 2021, 11, 2968-2986.	9.4	116
53	Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation. <i>Radiology</i> , 2014, 270, 1-2.	7.3	109
54	A mathematical model of ctDNA shedding predicts tumor detection size. <i>Science Advances</i> , 2020, 6, .	10.3	105

#	ARTICLE	IF	CITATIONS
55	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1422-1437.e10.	16.8	102
56	Targeting Unique Metabolic Properties of Breast Tumor Initiating Cells. <i>Stem Cells</i> , 2014, 32, 1734-1745.	3.2	97
57	Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. <i>Seminars in Radiation Oncology</i> , 2015, 25, 305-312.	2.2	97
58	Neurotrophic factor GDNF promotes survival of salivary stem cells. <i>Journal of Clinical Investigation</i> , 2014, 124, 3364-3377.	8.2	96
59	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	9.4	93
60	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8379-E8386.	7.1	90
61	T Cell Receptor-Independent Basal Signaling via Erk and Abl Kinases Suppresses RAG Gene Expression. <i>PLoS Biology</i> , 2003, 1, e53.	5.6	88
62	<i>ERBB2</i> -Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 833-842.	1.1	86
63	Genome-Scale Identification of Membrane-Associated Human mRNAs. <i>PLoS Genetics</i> , 2006, 2, e11.	3.5	84
64	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , 2017, 17, 453.	2.6	83
65	Pulmonary Ventilation Imaging Based on 4-Dimensional Computed Tomography: Comparison With Pulmonary Function Tests and ASPECT Ventilation Images. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 414-422.	0.8	81
66	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	14.3	80
67	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	1.1	79
68	Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1462-1465.	1.1	78
69	Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 715-719.	3.1	75
70	<i>GFPT2</i> -Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. <i>Cancer Research</i> , 2018, 78, 3445-3457.	0.9	75
71	Role of <i>KEAP1/NFE2L2</i> Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 274-281.	7.0	75
72	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	7.0	74

#	ARTICLE	IF	CITATIONS
73	Control of inflammation by stromal Hedgehog pathway activation restrains colitis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7545-E7553.	7.1	73
74	Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1504-1512.	0.8	71
75	Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease. Nature Communications, 2018, 9, 368.	12.8	71
76	A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 872-884.	0.8	69
77	Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy. Seminars in Radiation Oncology, 2017, 27, 197-208.	2.2	68
78	Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 84, 231-237.	0.8	66
79	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood, 2017, 130, 440-452.	1.4	66
80	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nature Communications, 2020, 11, 6410.	12.8	66
81	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. Clinical Cancer Research, 2014, 20, 5558-5569.	7.0	64
82	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv211.	6.3	64
83	Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology, 2022, 40, 585-597.	17.5	63
84	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 72-81.	0.8	62
85	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1044-1052.	0.8	61
86	Comparing functional genomic datasets: lessons from DNA microarray analyses of host-pathogen interactions. Current Opinion in Microbiology, 2001, 4, 95-101.	5.1	59
87	Deep segmentation networks predict survival of non-small cell lung cancer. Scientific Reports, 2019, 9, 17286.	3.3	59
88	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i> . Cancer Discovery, 2021, 11, 1736-1753.	9.4	59
89	Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunology, 2002, 3, 5.	2.2	56
90	Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D. Molecular Cancer Therapeutics, 2015, 14, 1951-1961.	4.1	56

#	ARTICLE	IF	CITATIONS
91	Differential gene expression in anatomical compartments of the human eye. <i>Genome Biology</i> , 2005, 6, R74.	9.6	55
92	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. <i>Journal of Clinical Investigation</i> , 2014, 124, 553-563.	8.2	53
93	4D CT lung ventilation images are affected by the 4D CT sorting method. <i>Medical Physics</i> , 2013, 40, 101907.	3.0	52
94	Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. <i>Journal of Neuro-Oncology</i> , 2008, 86, 133-141.	2.9	51
95	Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable. <i>Radiotherapy and Oncology</i> , 2020, 147, 217-220.	0.6	49
96	Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. <i>Lung Cancer</i> , 2012, 78, 219-224.	2.0	46
97	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2018, 24, 2688-2699.	7.0	45
98	Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. <i>Anti-Cancer Drugs</i> , 2019, 30, 537-541.	1.4	41
99	Radiological tumour classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , 2021, 3, 787-798.	16.0	41
100	High Retention and Safety of Percutaneously Implanted Endovascular Embolization Coils as Fiducial Markers for Image-Guided Stereotactic Ablative Radiotherapy of Pulmonary Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 85-90.	0.8	38
101	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 42-45.	2.0	37
102	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	1.6	37
103	A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. <i>Genome Biology</i> , 2020, 21, 107.	8.8	33
104	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 395-403.	1.1	33
105	Clinical Implementation of Intrafraction Cone Beam Computed Tomography Imaging During Lung Tumor Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 917-923.	0.8	32
106	Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. <i>Theranostics</i> , 2020, 10, 11707-11718.	10.0	32
107	A 3-D Riesz-Covariance Texture Model for Prediction of Nodule Recurrence in Lung CT. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 2620-2630.	8.9	31
108	Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 808-815.	0.8	31

#	ARTICLE	IF	CITATIONS
109	Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 119, 42-47.	2.0	31
110	Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation. <i>Cancer Research</i> , 2014, 74, 341-352.	0.9	30
111	Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA. <i>Clinical Chemistry</i> , 2018, 64, 307-316.	3.2	30
112	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 338-343.	0.6	29
113	Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e709-e715.	0.8	27
114	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). <i>Radiotherapy and Oncology</i> , 2016, 119, 454-460.	0.6	27
115	Identification and genetic manipulation of human and mouse oesophageal stem cells. <i>Gut</i> , 2016, 65, 1077-1086.	12.1	27
116	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. <i>Nature Communications</i> , 2019, 10, 5712.	12.8	27
117	Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3591-3591.	1.6	27
118	Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 920-926.	1.1	26
119	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 294-301.e3.	2.6	25
120	Data normalization considerations for digital tumor dissection. <i>Genome Biology</i> , 2017, 18, 128.	8.8	25
121	38, 2424-2429.	3.0	24
122	Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1413-1420.	1.1	22
123	¹⁸ F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1183-1192.	0.8	22
124	To SABR or Not to SABR? Indications and Contraindications for Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage, Oligometastatic, or Oligoprogressive Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2015, 25, 78-86.	2.2	20
125	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. <i>Journal of Oncology</i> , 2017, 2017, 1-5.	1.3	20
126	A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1098-1106.	0.8	20

#	ARTICLE	IF	CITATIONS
127	What the Diagnostic Radiologist Needs to Know about Radiation Oncology. <i>Radiology</i> , 2011, 261, 30-44.	7.3	19
128	Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. <i>Practical Radiation Oncology</i> , 2013, 3, 294-300.	2.1	19
129	Migration of implanted markers for image-guided lung tumor stereotactic ablative radiotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 77-89.	1.9	19
130	Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 588-594.	2.6	19
131	The Myc Connection: ES Cells and Cancer. <i>Cell</i> , 2010, 143, 184-186.	28.9	18
132	Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment?. <i>Cell Stem Cell</i> , 2010, 6, 502-503.	11.1	17
133	Analysis of Long-Term 4-Dimensional Computed Tomography Regional Ventilation After Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 683-690.	0.8	17
134	Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC. <i>European Radiology</i> , 2018, 28, 736-746.	4.5	17
135	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 199-222.	22.4	16
136	Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. <i>Practical Radiation Oncology</i> , 2014, 4, 272-278.	2.1	15
137	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2016-2025.	4.1	15
138	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. <i>Blood</i> , 2021, 138, 6-6.	1.4	15
139	SABR-COMET: harbinger of a new cancer treatment paradigm. <i>Lancet, The</i> , 2019, 393, 2013-2014.	13.7	14
140	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. <i>Cancer Research</i> , 2022, 82, 2838-2847.	0.9	14
141	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 6176-6186.	7.0	13
142	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucele Therapy. <i>Blood</i> , 2019, 134, 550-550.	1.4	13
143	A method for detecting and correcting feature misidentification on expression microarrays. <i>BMC Genomics</i> , 2004, 5, 64.	2.8	11
144	Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. <i>Clinical Lung Cancer</i> , 2016, 17, e17-e21.	2.6	11

#	ARTICLE	IF	CITATIONS
145	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 173-182.	2.0	11
146	The impact of audiovisual biofeedback on 4D functional and anatomic imaging: Results of a lung cancer pilot study. <i>Radiotherapy and Oncology</i> , 2016, 120, 267-272.	0.6	10
147	Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 114-114.	1.4	10
148	Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors. <i>Clinical Lung Cancer</i> , 2015, 16, 475-485.	2.6	9
149	Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors. <i>Practical Radiation Oncology</i> , 2017, 7, e525-e529.	2.1	9
150	Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling. <i>Blood</i> , 2019, 134, 551-551.	1.4	9
151	Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 130-130.	1.4	9
152	Molecular Determinants of Radiation Response in Non-“Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2015, 25, 67-77.	2.2	8
153	FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study. <i>Frontiers in Oncology</i> , 2019, 9, 467.	2.8	8
154	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1089-1089.	1.4	8
155	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. <i>Blood</i> , 2016, 128, 1752-1752.	1.4	8
156	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2930-2930.	1.4	8
157	Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2014, 9, 957-964.	1.1	7
158	Noninvasive pulmonary nodule elastometry by CT and deformable image registration. <i>Radiotherapy and Oncology</i> , 2015, 115, 35-40.	0.6	7
159	Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung. <i>Radiotherapy and Oncology</i> , 2017, 123, 270-275.	0.6	6
160	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. <i>JCO Precision Oncology</i> , 2017, 2017, 1-9.	3.0	6
161	Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 559-564.	1.3	6
162	Lung Volume Reduction After Stereotactic Ablative Radiation Therapy of Lung Tumors: Potential Application to Emphysema. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 216-223.	0.8	5

#	ARTICLE	IF	CITATIONS
163	Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. <i>Radiation Oncology</i> , 2016, 11, 40.	2.7	5
164	Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors. <i>Clinical Lung Cancer</i> , 2019, 20, 461-468.e2.	2.6	5
165	Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA. <i>Blood</i> , 2019, 134, 552-552.	1.4	5
166	Anatomic optimization of lung tumor stereotactic ablative radiation therapy. <i>Practical Radiation Oncology</i> , 2015, 5, e607-e613.	2.1	4
167	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021, 26, 523-532.	3.7	4
168	Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8518-8518.	1.6	4
169	Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling. <i>Blood</i> , 2018, 132, 672-672.	1.4	4
170	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 655-655.	1.4	4
171	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. <i>Blood</i> , 2017, 130, 826-826.	1.4	4
172	Predictive Radiation Oncology – A New NCI–DOE Scientific Space and Community. <i>Radiation Research</i> , 2022, 197, .	1.5	4
173	The effect of arm position on the dosimetry of thoracic stereotactic ablative radiation therapy using volumetric modulated arc therapy. <i>Practical Radiation Oncology</i> , 2014, 4, 192-197.	2.1	3
174	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non–Small-Cell Lung Cancer in the United States and Vietnam. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	3
175	Stereotactic ablative radiotherapy for central and ultra-central lung tumors. <i>Therapeutic Radiology and Oncology</i> , 2019, 3, 18-18.	0.2	3
176	Response Letter: Radiation therapy for COVID-19 pneumopathy. <i>Radiotherapy and Oncology</i> , 2020, 149, 238-239.	0.6	3
177	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. <i>Blood</i> , 2019, 134, 1600-1600.	1.4	3
178	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). <i>Blood</i> , 2020, 136, 49-50.	1.4	3
179	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7511-7511.	1.6	3
180	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. <i>Cancers</i> , 2022, 14, 2479.	3.7	3

#	ARTICLE	IF	CITATIONS
181	Practical workflow for rapid prototyping of radiation therapy positioning devices. <i>Practical Radiation Oncology</i> , 2017, 7, 442-445.	2.1	2
182	Line-Enhanced Deformable Registration of Pulmonary Computed Tomography Images Before and After Radiation Therapy With Radiation-Induced Fibrosis. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303461774941.	1.9	2
183	Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 76-85.	2.0	2
184	Increases in Serial Pretreatment 18F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2019, 4, 429-437.	1.2	2
185	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	1.6	2
186	A Feasibility Study of Single-inhalation, Single-energy Xenon-enhanced CT for High-resolution Imaging of Regional Lung Ventilation in Humans. <i>Academic Radiology</i> , 2019, 26, 38-49.	2.5	2
187	Stem Cells, Cell Differentiation, and Cancer. , 2020, , 97-107.e5.		2
188	Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. <i>Clinical Lung Cancer</i> , 2021, 22, e673-e677.	2.6	2
189	Overcoming Radioresistance of Lung Cancer Stem Cells. <i>Stem Cells and Cancer Stem Cells</i> , 2014, , 117-127.	0.1	2
190	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
191	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9000-9000.	1.6	2
192	Noninvasive molecular subtyping and risk stratification of DLBCL.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7554-7554.	1.6	2
193	Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1144-1153.	0.8	2
194	The Optimal Use of Radiotherapy in Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 107-114.	4.9	1
195	PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-“Small Cell Lung Cancers and Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2016, 11, S312-S313.	1.1	1
196	MA17.07 Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S445.	1.1	1
197	Genomic feature selection by coverage design optimization. <i>Journal of Applied Statistics</i> , 2018, 45, 2658-2676.	1.3	1
198	Phased variants improve DLBCL minimal residual disease detection at the end of therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7565-7565.	1.6	1

#	ARTICLE	IF	CITATIONS
199	Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.. Journal of Clinical Oncology, 2021, 39, 8533-8533.	1.6	1
200	Mechanisms and Markers of Clinical Radioresistance. Cancer Drug Discovery and Development, 2020, , 63-96.	0.4	1
201	Stem Cells, Cell Differentiation, and Cancer. , 2014, , 98-107.e3.		1
202	Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.. Journal of Clinical Oncology, 2016, 34, e20500-e20500.	1.6	1
203	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. Blood, 2016, 128, 4107-4107.	1.4	1
204	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. Blood, 2018, 132, 2838-2838.	1.4	1
205	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. Blood, 2021, 138, 709-709.	1.4	1
206	Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer, 2022, 23, 282-289.	2.6	1
207	Mechanisms of Radioresistance in Cancer Stem Cells. , 2011, , 345-360.		0
208	In Reply to Song etÂal.. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194.	0.8	0
209	In Reply to Drs. Koch and Evans. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1605.	0.8	0
210	Deep sequencing of circulating tumor DNA for personalized cancer detection and monitoring. Annals of Oncology, 2015, 26, vii3.	1.2	0
211	Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA. , 2016, , .		0
212	(OA02) Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, e1-e2.	0.8	0
213	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. Journal of Clinical Oncology, 2014, 32, 8504-8504.	1.6	0
214	Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.. Journal of Clinical Oncology, 2014, 32, 11016-11016.	1.6	0
215	Cancer Stem Cells and Tumor Radioresistance. , 2015, , 519-531.		0
216	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8539-8539.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.. Journal of Clinical Oncology, 2015, 33, 8570-8570.	1.6	0
218	Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.. Journal of Clinical Oncology, 2016, 34, 8510-8510.	1.6	0
219	Sinoatrial node dysfunction after stereotactic ablative radiation therapy in the chest.. Journal of Clinical Oncology, 2017, 35, 132-132.	1.6	0
220	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. Journal of Clinical Oncology, 2017, 35, TPS5094-TPS5094.	1.6	0
221	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood, 2018, 132, 2861-2861.	1.4	0
222	Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 491-491.	1.4	0
223	Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies. Blood, 2019, 134, 885-885.	1.4	0
224	Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. Blood, 2021, 138, 37-37.	1.4	0